The epidermal growth factor receptor in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 2, Issue 2, 1997, Pages 131-141

  Fox, Stephen B ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adipose tissue; Embryogenesis; Prognostic phenotype; Sialoadenectomy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND;

BREAST; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LACTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BREAST; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTATION; LIGANDS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0031107250     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026399613946     Document Type: Article

References (110)

1. B. Gusterson, G. Cowley, J. A. Smith, and B. Ozanne (1984). Cellular localization of human epidermal growth factor receptor. Cell Biol. Int. Rep. 8:649-658.
2. F. X. Real, W. J. Rettig, P. G. Chesa, M. R. Melamed, L. J. Old, and J. Mendelsohn (1986). Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res. 46:4726-4731.
3. A. L. Harris, (1989). Epidermal growth factor receptor in human breast cancer. Recent Results Cancer Res. 113:70-77.
4. S. Okamoto and T. Oka (1984). Evidence for physiological function of epidermal growth factor: pregestational sialoadenectomy of mice decreases milk production and increases offspring mortality during lactation period. Proc. Natl. Acad. Sci. U.S.A. 81:6059-6063.
5. K. J. Fowler, F. Walker, W. Alexander, M. L. Hibbs, E. C. Nice, R. M. Bohmer, G. B. Mann, C. Thumwood, R. Maglitto, J. A. Danks, R. Chetty, A. Burgess, and A. Dunn (1995). A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc. Natl. Acad. Sci. U.S.A. 92:1465-1469.
6. S. Scala, T. Saeki, A. Lynch, D. Salomon, M. J. Merino, and S. E. Bates (1995). Coexpression of TGF alpha, epidermal growth factor receptor, and P-glycoprotein in normal and benign diseased breast tissues. Diagn. Mol. Pathol. 4:136-142.
7. I. Damjanov, B. Mildner, and B. Knowles (1986). Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab. Invest. 55:588-592.
8. P. Moller, G. Mechtersheimer, M. Kaufmann, G. Moldenhauer, F. Momburg, T. Mattfeldt, and H. F. Otto (1989). Expression of epidermal growth factor receptor in benign and malignant primary tumors of the breast. Virchows Arch. A Pathol. Anat. Histopathol. 414:157-164.
9. Y. Tsutsumi, S. P. Naber, R. A. DeLellis, H. J. Wolfe, P. J. Marks, S. J. McKenzie, and S. Yin (1990). neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Hum. Pathol. 21:750-758.
10. R. Dittadi, P. M. Donisi, A. Brazzale, L. Cappellozza, G. Bruscagnin, and M. Gion (1993). Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue. Br. J. Cancer. 67:7-9.
11. M. T. Travers, L. P. Barrett, U. Berger, Y. A. Luqmani, J. C. Gazet, T. J. Powles, and R. C. Coombes (1988). Growth factor expression in normal, benign, and malignant breast tissue Br. Med. J. Clin. Res. Ed. 296:1621-1624.
12. Y. Mizukami, A. Nonomura, M. Noguchi, T. Taniya, N. Koyasaki, Y. Saito, T. Hashimoto, F. Matsubara, and N. Yanihara (1991). Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res. 11:xx-xx.
13. T. Wada, M. Yasutomi, K. Yamada, M. Kunikata, H. Higashiyama, P. Shrestha, and M. Mori (1991). Immunohistochemical expression of epidermal growth factor receptor in benign and malignant lesions of the breast. Acta Histochem. Cytochem. 24:449-455.
14. M. Zelada-Hedman, G. Werer, P. Collins, M. Backdahl, I. Perez, S. Franco, J. Jimenez, J. Cruz, M. Torroella, and M. Nordenskjold (1994). High expression of the EGFR in fibroadenomas compared to breast carcinomas. Anticancer Res. 14:1679-1688.
15. J. R. Sainsbury, G. Sherbet, J. R. Farndon, and A. L. Harris (1985). Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1:364-366.
16. F. Battaglia, G. Scambia, S. Rossi, P. B. Panici, R. Bellantone, G. Polizzi, P. Querzoli, R. Negrini, S. Iacobelli, F. Crucitti, and et. al. (1980). Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement Eur. J. Cancer Clin. Oncol. 24:1685-1690. Published erratum appears in Eur. J. Cancer Clin. Oncol. 25(3):577.
17. F. Pekonen, S. Partanen, T. Makinen, and E. M. Rutanen (1988). Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 48:1343-1347.
18. T. Mori, T. Morimoto, K. Komaki, and Y. Monden (1991). Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 68:532-537.
19. A. Rosenthal, P. B. Lindquist, T. S. Bringman, D. V. Goeddel, and R. Derynck (1986). Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell 46:301-309.
20. P. P. DiFiore, J. H. Pierce, T. P. Fleming, R. Hazan, A. Ullrich, C. R. King, J. Schlessinger, and S. A. Aaronson (1987). Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51:1063-1070.
21. M. C. Maa, T. H. Leu, D. J. McCarley, R. C. Schatzman, and S. J. Parsons (1995). Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. U.S.A. 92:6981-6985.
22. E. Sandgren, N. Luetteke, R. Palmiter, R. Brinster, and D. Lee (1990). Overexpression of TGFa in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121-1135.
23. P. G. Koenders, D. Faverly, L. V. Beex, E. D. Bruggink, C. B. Kienhuis, and T. J. Benraad (1992). Epidermal growth factor receptors in human breast cancer: a plea for standardization of assay methodology. Eur. J. Cancer 28:693-697.
24. A. Rallet, M. J. Faroux, S. Theobald, L. M. Caquot, C. Pourny, M. Pluot, and J. C. Jardillier (1994). Epidermal growth factor receptors in breast cancer: comparison of radioligand and immunocytochemical assays. Anticancer Res. 14:1417-1421.
25. H. Iwase, S. Kobayashi, Y. Itoh, T. Kuzushima, H. Yamashita, H. Iwata, A. Naito, T. Yamashita, K. Itoh, and A. Masaoka (1993). Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Res. Treat. 28:215-221.
26. J. C. Newby, R. P. A'Hern, R. D. Leek, I. E. Smith, A. L. Harris, and M. Dowsett (1995). Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Br. J. Cancer 71:1237-1242.
27. S. A. Chrysogelos, R. I. Yarden, A. H. Lauber, and J. M. Murphy (1994). Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res. Treat. 31:227-236.
28. E. Petrangeli, C. Lubrano, L. Ravenna, A. Vacca, M. R. Cardillo, L. Salvatori, F. Sciarra, L. Frati, and A. Gulino (1995). Gene methylation of estrogen and epidermal growth-factor receptors in neoplastic and perineoplastic breast tissues. Br. J. Cancer 72:973-975.
29. E. Petrangeli, C. Lubrano, L. Ravenna, A. Vacca, M. R. Cardillo, L. Salvatori, F. Sciarra, L. Frati, and A. Gulino (1995). Gene methylation of oestrogen and epidermal growth factor receptors in neoplastic and perineoplastic breast tissues. Br. J. Cancer 72:973-975.
30. S. LeJeune, R. Leek, E. Horak, G. Plowman, M. Greenall, and A. L. Harris (1993). Amphiregulin, epidermal growth factor receptor and oestrogen receptor expression in human primary breast cancer. Cancer Res. 53:3597-3602.
31. L. C. Groenen, E. C. Nice, and A. W. Burgess (1994). Structure-function-relationships for the EGF/tgf-alpha family of mitogens. Growth Factors 11:235-257.
32. H. Toyoda, T. Komurasaki, D. Uchida, Y. Takayama, T. Isobe, T. Okuyama, and K. Hanada (1995). Epiregulin - a novel epidermal growth-factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 270:7495-7500.
33. R. Lupu, M. Cardillo, L. Harris, M. Hijazi, and K. Rosenberg (1995). Interaction between erbb-receptors and heregulin in breast-cancer tumor progression and drug-resistance. Semin Cancer Biol. 6:135-145.
34. T. Saeki, D. S. Salomon, G. R. Johnson, W. J. Gullick, K. Mandai, K. Yamagami, S. Moriwaki, M. Tanada, S. Takashima, and E. Tahara (1995). Association of epidermal growth factor-related peptides and type-1 receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn. J. Clin. Oncol. 25:240-249.
35. H. I. Scher, A. Sarkis, V. Reuter, D. Cohen, G. Netto, D. Petrylak, P. Lianes, Z. Fuks, J. Mendelsohn, and C. Cordoncardo (1995). Changing pattern of expression of the epidermal growth-factor receptor and transforming growth-factor-alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1:545-550.
36. N. Normanno, N. Kim, D. Z. Wen, K. Smith, A. L. Harris, G. Plowman, G. Colletta, F. Ciardiello, and D. S. Salomon (1995). Expression of messenger-RNA for amphiregulin, heregulin and cripto-1, 3 new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res. Treat. 35:293-297.
37. S. Fitzpatrick, J. Brightwell, J. Wittliff, G. Barrows, and G. Schultz (1984). Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res. 44:3448-3453.
38. P. Bolufer, F. Miralles, A. Rodriguez, C. Vazquez, A. Lluch, C. J. Garcia, and T. Olmos (1990). Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics. Eur. J. Cancer 26:283-290.
39. C. Charpin, B. Devictor, P. Bonnier, L. Andrac, M. N. Lavaut, C. Allasia, and L. Piana (1993). Epidermal growth factor receptor in breast cancer: correlation of quantitative immunocytochemical assays to prognostic factors. Breast Cancer Res. Treat. 25:203-210.
40. J. G. Klijn, M. P. Look, H. Portengen, F. J. Alexieva, P. W. van, and J. A. Foekens (1994). The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res. Treat. 29:73-83.
41. M. J. Railo, K. V. Smitten, and F. Pekonen (1994). The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients. Acta Oncol. 33:13-17.
42. F. Spyratos, P. M. Martin, K. Hacene, C. Andrieu, S. Romain, J. L. Floiras, and H. Magdelenat (1994). Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay - a retrospective study. Breast Cancer Res. Treat. 29:85-95.
43. M. Toi, T. Tominaga, A. Osaki, and T. Toge (1994). Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res. Treat. 29:51-58.
44. R. Wyss, D. Fabbro, R. Regazzi, C. Borner, A. Takahashi, and U. Eppenberger (1987). Phorbol ester and epidermal growth factor receptors in human breast cancer. Anticancer Res. 7:721-727.
45. S. B. Fox, K. Smith, J. Hollyer, M. Greenall, D. Hastrich, and A. L. Harris (1994). The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat. 29:41-49.
46. V. Cappelletti, M. Brivio, P. G. Miodini, D. Coradini, and G. Di Fronzo (1988). Simultaneous estimation of epidermal growth factor receptors and steroid receptors in a series of 136 resectable primary breast tumors. Tumor Biol. 9:200-211.
47. P. J. Hainsworth, M. A. Henderson, R. G. Stillwell, and R. C. Bennett (1991). Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. Eur. J. Surg. Oncol. 17:9-15.
48. M. Bilous, J. Milliken, and J. M. Mathijs (1992). Immunocytochemistry and in situ hybridization of epidermal growth factor receptor and relation to prognostic factors in breast cancer. Eur. J. Cancer.
49. G. Gasparini, P. Boracchi, P. Bevilacqua, M. Mezzetti, F. Pozza, and N. Weidner (1994). A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res. Treat. 29:59-71.
50. J. C. Delarue, S. Friedman, H. Mouriesse, L. F. May, G. H. Sancho, and G. Contesso (1988). Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors. Breast Cancer Res. Treat. 11:173-178.
51. M. Bolla, M. Chedin, C. Souvignet, J. Marron, C. Arnould, and E. Chambaz (1990). Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors. Breast Cancer Res. Treat. 16:97-102.
52. J. R. Sainsbury, A. J. Malcolm, D. R. Appleton, J. R. Farndon, and A. L. Harris (1985). Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J. Clin. Pathol. 38:1225-1228.
53. P. G. Koenders, L. V. Beex, M. A. Geurts, J. J. Heuvel, C. B. Kienhuis, and T. J. Benraad (1991). Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 51:4544-4548.
54. A. K. Sharma, K. Horgan, J. A. Douglas, R. McClelland, J. Gee, and R. Nicholson (1994). Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br. J. Cancer. 69:1032-1037.
55. C. Doglioni, T. A. Dei, L. Laurino, C. Chiarelli, M. Barbareschi, and G. Viale (1994). The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 424:47-51.
56. R. D. Leek, L. Kaklamanis, F. Pezzella, K. C. Gatter, and A. L. Harris (1994). BCL-2 in normal human breast and carcinoma, association with oestrogen receptor positive, epidermal growth factor receptor negative tumors and in situ cancer. Br. J. Cancer 69:135-139.
57. G. Cattoretti, F. Rilke, S. Andreola, L. D'Amato, and D. Delia (1988). P53 expression in breast cancer. Int. J. Cancer 41:178-183.
58. D. N. Poller, C. E. Hutchings, M. Galea, J. A. Bell, R. A. Nicholson, C. W. Elston, R. W. Blamey, and I. O. Ellis (1992). p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br. J. Cancer 66:583-588.
59. D. J. Dabbs (1995). Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2. Mod. Pathol. 8:631-642.
60. F. Wrba, A. Reiner, E. Ritzinger, J. H. Holzner, and G. Reiner (1988). Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study. Pathol. Res. Pract. 183:25-29.
61. R. I. Nicholson, R. A. McClelland, J. M. Gee, D. L. Manning, P. Cannon, J. F. Robertson, I. O. Ellis, and R. W. Blarney (1994). Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat. 29:117-125.
62. G. K. Needham, S. Nicholson, B. Angus, J. R. Farndon, and A. L. Harris (1988). Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res. 48:6603-6607.
63. G. G. McIntosh, J. J. Anderson, I. Milton, M. Steward, A. H. Parr, M. D. Thomas, J. A. Henry, B. Angus, T. W. Lennard, and C. H. Home (1995). Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891.
64. J. Folkman (1990). What is the evidence that tumors are angiogenesis dependent. J. Natl. Cancer Inst. 82:4-6.
65. G. Rice and M. Bevilacqua (1988). An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 246:1303-1306.
66. A. B. Schreiber, M. E. Winkler, and R. Derynck (1986). Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232: 1250-1253.
67. C. Goldman, J. Kim, W.-L. Wong, V. King, T. Brock, and G. Gillespie (1993). Epidermal growth factor stimulates vascular endothelial cell growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4:121-133.
68. S. B. Fox, R. D. Leek, K. Smith, J. Hollyer, M. Greenall, and A. L. Harris (1994). Tumor angiogenesis in node-negative breast carcinomas - relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res. Treat. 29:109-116.
69. N. Weidner and G. Gasparini (1994). Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res. Treat. 29:97-107.
70. E. Horak, R. Leek, N. Klenk, S. LeJeune, K. Smith, N. Stuart, M. Greenall, K. Stepniewska, and A. L. Harris (1992). Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 340:1120-1124.
71. N. Weidner, J. Folkman, F. Pozza, P. Bevilacqua, E. Allred, D. Moore, S. Meli, and G. Gasparini (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J. Natl. Cancer Inst. 84:1875-1887.
72. J. R. Sainsbury, J. R. Farndon, G. K. Needham, A. J. Malcolm, and A. L. Harris (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398-1402.
73. S. Nicholson, J. Richard, C. Sainsbury, P. Halcrow, P. Kelly, B. Angus, C. Wright, J. Henry, J. R. Farndon, and A. L. Harris (1991). Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer 63:146-150.
74. J. G. Klijn, P. M. Berns, P. I. Schmitz, and J. A. Foekens (1992). The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrinol. Rev. 13:3-17.
75. J. G. Klijn, P. M. Berns, P. I. Schmitz, and J. A. Foekens (1993). Epidermal growth factor receptor (EGF-R) in clinical breast cancer: update 1993. Endocrinol. Rev. Monographs, 1:171-174.
76. M. A. Rios, A. Macias, R. Perez, A. Lage, and L. Skoog (1988). Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res. 8:173-176.
77. S. Costa, H. Stamm, A. Almendral, H. Ludwig, R. Wyss, D. Fabbro, A. Ernst, A. Takahashi, and U. Eppennberger (1988). Predictive value of EGF receptor in breast cancer. Lancet 2:1258.
78. M. Grimaux, S. Romain, Y. Remvikos, P. M. Martin, and H. Magdelenat (1989). Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res. Treat. 14:77-90.
79. J. A. Foekens, H. Portengen, P. W. van, A. M. Trapman, J. C. Reubi, F. J. Alexieva, and J. G. Klijn (1989). Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res.
80. S. Lewis, A. Locker, J. H. Todd, J. A. Bell, R. Nicholson, C. W. Elston, R. W. Blamey, and I. O. Ellis (1990). Expression of epidermal growth factor receptor in breast carcinoma. J. Clin. Pathol. 43:385-389.
81. F. Spyratos, J. C. Delarue, C. Andrieu, R. Lidereau, M. H. Champeme, K. Hacene, and M. Brunet (1990). Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res. Treat. 17:83-89.
82. M. Toi, A. Osaki, H. Yamada, and T. Toge (1991). Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer 27:977-980.
83. R. Hawkins, E. Killen, I. Whittle, W. Jack, U. Chetty, and R. Prescott (1991). Epidermal growth factor receptors in intracranial and breast tumors: their clinical significance. Br. J. Cancer 63:553-560.
84. P. Shrestha, K. Yamada, T. Wada, S. Maeda, M. Watatani, M. Yasutomi, H. Takagi, and M. Mori (1992). Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. Virchows Arch A Pathol. Anat. Histopathol. 421:193-202.
85. G. Gasparini, P. Bevilacqua, F. Pozza, S. Meli, P. Boracchi, E. Marubini, and J. Sainsbury (1992), Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br. J. Cancer 66:970-976.
86. A. Osaki, M. Toi, H. Yamada, H. Kawami, K. Kuroi, and T. Toge (1992). Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am. J. Surg. 164:323-326.
87. M. Bolla, M. Chedin, M. Colonna, J. Marron, P. B. Rostaing, and E. Chambaz (1992). Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur. J. Cancer 28A:1052-1054.
88. P. Murray, P. Barrett-Lee, M. Travers, Y. Luqmani, T. Powles, and R. Coombes (1993). The prognostic significance of transforming growth factors in human breast cancer. Br. J. Cancer 67:1408-1412.
89. P. G. Koenders, L. V. Beex, C. B. Kienhuis, P. W. Kloppenborg, and T. J. Benraad (1993). Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res. Treat. 25:21-27.
90. M. Noguchi, Y. Mizukami, K. Kinoshita, M. Earashi, M. Thomas, and I. Miyazaki (1994). The prognostic significance of epidermal growth factor receptor expression in breast cancer. Surg. Today. 24:889-894.
91. G. Gasparini, F. Pozza, and A. Harris (1993). Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst. 85:1206-1219.
92. H. S. Earp, T. L. Dawson, X. Li, and H. Yu (1995). Heterodimerization and functional interaction between EGF receptor family members - a new signaling paradigm with implications for breast-cancer research. Breast Cancer Res. Treat. 35:115-132.
93. C. Wright, B. Angus, S. Nicholson, J. R. C. Sainsbury, J. Cairns, W. J. Gullick, P. Kelly, A. L. Harris, and C. H. W. Horne (1989). Expression of c-erbB-2 oncoprotein: a prognostic indicator in breast cancer. Cancer Res. 49:2087-2090.
94. E.B.C.T.C. Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15; 71-85.
95. S. Nicholson, P. Halcrow, J. R. C. Sainsbury, B. Angus, P. Chambers, J. R. Farndon, and A. L. Harris (1988). Epidermal growth factor receptor status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br. J. Cancer 58:810-814.
96. S. Nicholson, J. R. C. Sainsbury, P. Halcrow, P. Chambers, J. R. Farndon, and A. L. Harris, (1989). Epidermal growth factor receptor expression is associated with lack of response to endocrine therapy in patients with recurrent breast cancer. Lancet 1:182-185.
97. J. G. Klijn, E. M. Berns, and J. A. Foekens (1993). Prognostic factors and response to therapy in breast cancer. Cancer Surv. 18:165-198.
98. S. G. Archer, A. Eliopoulos, D. Spandidos, D. Barnes, I. O. Ellis, R. W. Blamey, R. I. Nicholson, and J. F. Robertson (1995). Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer 72:1259-1266.
99. C. Wright, J. Cairns, B. J. Cantwell, A. R. Cattan, A. G. Hall, A. L. Harris, and C. H. W. Home (1992). Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Brit. J. Cancer 65:211-274.
100. C. Wright, S. Nicholson, B. Angus, J. R. C. Sainsbury, J. Farndon, J. Cairns, A. L. Harris, and C. H. W. Horne, (1992). Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Brit. J. Cancer 65:118-121.
101. N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn (1995). Biological efficacy of a chimeric antibody to the epidermal growth-factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1:1311-1318.
102. E. Tosi, O. Valota, D. R. M. Negri, E. Adobati, A. Mazzoni, R. Meazza, S. Ferrini, M. I. Colnaghi, and S. Canevari (1995). Antitumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal-antibody and its f(ab′)(2) fragment against high-EGFR-expressing and low-EGFR-expressing carcinomas in nude-mice. Int. J. Cancer 62:643-650.
103. J. Baselga and J. Mendelsohn (1994). The epidermal growth factor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat. 29:127-138.
104. C. J. Wikstrand, L. P. Hale, S. K. Batra, M. L. Hill, P. A. Humphrey, S. N. Kurpad, R. E. McLendon, D. Moscatello, C. N. Pegram, and C. J. Reist (1995). Monoclonal-antibodies against EGFR viii are tumor-specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:3140-3148.
105. A. V. Patterson, H. Zhang, A. Moghaddam, R. Bicknell, D. C. Talbot, I. J. Stratford, and A. L. Harris (1995). Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deozyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Brit. J. Cancer 72:669-675.
106. D. Fitzgerald and I. Pastan (1989). Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst. 81:1455-1463.
107. J. Kirk, J. Carmichael, I. J. Stratford, and A. J. Harris (1994). Selective toxicity of TGFα-PE40 to ERFR-positive cell lines: Selection protection of low EGFR-expressing cell lines by EGF. Brit. J. Cancer 69:988-994.
108. R. Kroning, J. A. Jones, D. K. Horn, C. C. Chuang, R. Sanga, G. Los, S. B. Howell, and R. D. Christen (1995). Enhancement of drug-sensitivity of human malignancies by epidermal growth-factor. Br. J. Cancer 72:615-619.
109. A. Cuarteroplaza, E. Martinez-Miralles, R. Rosell, C. Vadellnadal, M. Farre, and F. X. Real (1996). Radiolocalization of squamous lung-carcinoma with i-131-labeled epidermal growth-factor Clin. Cancer Res. 2:13-20.
110. A. Levitzki (1990). Tyrphostins - potential antiproliferative agents and novel molecular tools. Biochem. Pharmacol. 40:913-918.